银杏达莫注射液联合替格瑞洛治疗非ST段抬高型急性冠脉综合征的临床研究  

Clinical study on Ginkgo Leaf Extract and Dipyridamole Injection combined with ticagrelor in treatment of non-ST-segment elevation acute coronary syndrome

作　　者：叶晓歌[1] 范丽勇[2] 周延平[1] 姜增凯[1] YE Xiao-ge;FAN Li-yong;ZHOU Yan-ping;JIANG Zeng-kai(Department of Pharmacy, Nanyang Second People's Hospital, Nanyang 473000, China;Department of Cardiology, Nanyang Second People's Hospital, Nanyang 473000, China)

机构地区：[1]南阳市第二人民医院药学部,河南南阳473000 [2]南阳市第二人民医院心内科,河南南阳473000

出　　处：《现代药物与临床》2019年第3期657-662,共6页Drugs & Clinic

摘　　要：目的探讨银杏达莫注射液联合替格瑞洛治疗非ST段抬高型急性冠脉综合征的临床疗效。方法选取南阳市第二人民医院2016年10月—2018年4月收治的非ST段抬高型急性冠脉综合征患者96例,根据治疗方式的不同将患者分为对照组和治疗组,每组各48例。对照组口服替格瑞洛片,初次剂量为2片/次,然后1片/次,2次/d。治疗组在对照组基础上滴注治疗银杏达莫注射液,20mL加入250mL生理盐水,2次/d。两组患者共治疗14d。观察两组患者临床疗效和心电图疗效,同时比较治疗前后两组患者心功能指标水平、症状缓解情况、血清超敏C-反应蛋白(hs-CRP)和细胞外基质肌腱蛋白(TN-C)水平及心血管不良事件(MACCE)发生情况。结果治疗后,对照组临床疗效和心电图疗效分别为77.08%和79.17%,均分别显著低于治疗组的93.75%和95.83%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)、hs-CRP和TN-C水平均显著低于治疗前(P<0.05),左室射血分数(LVEF)值显著高于治疗前(P<0.05),且治疗组患者上述指标水平明显好于对照组(P<0.05)。治疗后,两组每次心绞痛发作持续时间、每日心绞痛发作频率、每日硝酸甘油用量均显著降低(P<0.05),且治疗组症状缓解情况明显好于对照组(P<0.05)。治疗组患者MACCE发生率为4.16%,显著低于对照组的14.58%,两组比较差异具有统计学意义(P<0.05)。结论银杏达莫注射液联合替格瑞洛治疗非ST段抬高型急性冠脉综合征临床疗效显著,可有效的改善患者心功能、临床症状,降低血清hs-CRP、TN-C水平及MACCE发生率。Objective To investigate the clinical efficacy of Ginkgo Leaf Extract and Dipyridamole Injection combined with ticagrelor in treatment of non-ST-segment elevation acute coronary syndrome. Methods Patients(96 cases) with non-ST-segment elevation acute coronary syndrome in Nanyang Second People’s Hospital from October 2016 to April 2018 were divided into control and treatment groups according to different treatments, and each had 48 cases. Patients in the control group were po administered with Ticagrelor Tablets, and the initial dose was 2 tablets/time, then 1 tablet/time, twice daily. Patients in the treatment group were iv administered with Ginkgo Leaf Extract and Dipyridamole Injection on the basis of the control group, 20 mL added into 250 mL normal saline, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy and ECG efficacy was evaluated,and the cardiac function indicators, the improvement of symptoms, serum hs-CRP and TN-C levels, and the incidence of MACCE in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and ECG efficacy in the control group were 77.08% and 79.17%, which were significantly lower than 93.75% and 95.83% in the treatment group, respectively, and there were differences between two groups(P < 0.05). After treatment, the LVESV, LVEDV, hs-CRP and TN-C levels in two groups were significantly decreased(P < 0.05), but LVEF levels were significantly increased(P < 0.05), and these indexes levels in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the duration of angina attack, the frequency of angina attack and the dosage of nitroglycerin in two groups was significantly decreased(P < 0.05), and the improvement of symptoms in the treatment group was significantly better than those in the control group(P < 0.05). The incidence of MACCE in the treatment group was 4.16%, which was significantly lower than 14.58% in the control group, with significant

关 键 词：银杏达莫注射液 替格瑞洛片 非ST段抬高型急性冠脉综合征 超敏C-反应蛋白 细胞外基质肌腱蛋白 左室射血分数 心血管不良事件 

分 类 号：R972[医药卫生—药品]